Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

Rhea-AI Summary

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call and audio webcast scheduled for May 14, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021, which ended on March 31, 2021, along with a business overview. The company's proprietary DNAbilize^® antisense RNAi nanoparticle technology is being utilized to develop targeted cancer drugs, including its lead candidate, prexigebersen, currently in Phase 2 trials for blood cancers. This event will be accessible via phone or on the company's website.

Positive

• Bio-Path's lead product candidate, prexigebersen, is in a Phase 2 study for blood cancers, indicating ongoing clinical development.
• The company is considering a drug modification, prexigebersen-A, for Phase 1 studies in solid tumors, suggesting potential pipeline expansion.

Negative

• None.

HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 14, 2021 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2021 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5064037. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies. For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings report its financial results for Q1 2021?

Bio-Path Holdings will report its financial results for Q1 2021 on May 14, 2021.

What is the focus of Bio-Path Holdings' drug development?

Bio-Path Holdings focuses on developing cancer drugs using its DNAbilize^® antisense RNAi nanoparticle technology.

What is the current status of prexigebersen?

Prexigebersen is in a Phase 2 clinical study targeting blood cancers.

How can I access the live audio webcast of the conference call?

The live audio webcast can be accessed on Bio-Path Holdings' website or by calling the designated phone numbers.

What is the significance of the May 14, 2021, conference call for investors?

The conference call will provide important updates on financial performance and business developments, which are crucial for investors.